Market & Industry Briefs
Executive Summary
Brief summaries of recent medtech market and industry developments. This month we cover what might be inhaled insulin's death knell, MetaCure's play in interventional diabetes and Novartis' deal with Alcon, and the US fracture fixation market.
You may also be interested in...
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover MannKind's positive inhaled insulin results, Medtrnoic's acquisition of CryoCath, Allergan's positive migraine results, and a new large-scale trial to assess late-stent thrombosis.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover MannKind's positive inhaled insulin results, Medtrnoic's acquisition of CryoCath, Allergan's positive migraine results, and a new large-scale trial to assess late-stent thrombosis.
Novartis' New Kind of Pharma Deal
Novartis' two-step, $39 billion agreement to take a majority share of eye-group Alcon represents a very new kind of pharma deal: with pharma re-defined to include consumer care and surgery; and, for the first few years at least, with the buyer remaining an arm's length investor.